Marisa Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marisa Fernández has a total of 499 co-authors. Here are the top co-authors by number of shared publications:
- Karina Andrea Gomez
Laboratorio de Inmunología de las Infecciones por Tripanosomátidos, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
5 shared publications Yolanda Hernández
Minist Salud, ANLIS Malbran, Inst Nacl Parasitol Dr Mario Fatala Chaben, Buenos Aires, DF, Argentina
5 shared publications- Alejandro Rísquez
Faculty of Medicine, Universidad Central de Venezuela, Caracas, Venezuela
4 shared publications - Alfonso J. Rodriguez-Morales
Faculty of Health Sciences, Universidad Científica del Sur, Lima 15067, Peru
4 shared publications - Baruch Diaz
Travel Medicine Clinic, Faculty of Medicine, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
4 shared publications Bruno Lococo
Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina
4 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 4 July 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- p. 103009
Reducing Communicable-Disease Risk After Earthquakes: Vaccination and Prevention Lessons for Venezuela’s Doublet
- 4 July 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- p. 103009
Top Cited PapersOpen AccessReducing Communicable-Disease Risk After Earthquakes: Vaccination and Prevention Lessons for Venezuela’s Doublet
- Open Access
- 28 May 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 73, 102995
The 2026 FIFA World Cup: Communicable disease risks and advice for visitors to Canada, the United States, and Mexico
- 28 May 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 73, 102995
Open AccessThe 2026 FIFA World Cup: Communicable disease risks and advice for visitors to Canada, the United States, and Mexico
- Open Access
- 2 July 2025
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 67, 102871
Yellow fever in South America – A plea for action and call for prevention also in travelers from SLAMVI, ESGITM, EVASG, ALEIMC, GEPI-SEIMC, SEMEVI, and CMTZMV-ACIN
- 2 July 2025
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 67, 102871
Open AccessYellow fever in South America – A plea for action and call for prevention also in travelers from SLAMVI, ESGITM, EVASG, ALEIMC, GEPI-SEIMC, SEMEVI, and CMTZMV-ACIN
- Top Cited PapersOpen Access
- 18 March 2025
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 65, 102839
Infectious diseases prevention and vaccination in migrants in Latin America: The challenges of transit through the treacherous Darien gap, Panama
- 18 March 2025
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 65, 102839
Top Cited PapersOpen AccessInfectious diseases prevention and vaccination in migrants in Latin America: The challenges of transit through the treacherous Darien gap, Panama
- Open Access
- 18 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1202
Characterization of Novel Trypanosoma cruzi-Specific Antigen with Potential Use in the Diagnosis of Chagas Disease
Chagas disease is caused by the parasite Trypanosoma cruzi. In humans, it evolves into a chronic disease, eventually resulting in cardiac, digestive, and/or neurological disorders. In the present study, we characterized a novel T. cruzi antigen named Tc323 (TcCLB.504087.20), recognized by a single-chain monoclonal antibody (scFv 6B6) isolated from the B cells of patients with cardiomyopathy related to chronic Chagas disease. Tc323, a ~323 kDa protein, is an uncharacterized protein showing putative quinoprotein alcohol dehydrogenase-like domains. A computational molecular docking study revealed that the scFv 6B6 binds to an internal domain of Tc323. Immunofluorescence microscopy and Western Blot showed that Tc323 is expressed in the main developmental forms of T. cruzi, localized intracellularly and exhibiting a membrane-associated pattern. According to phylogenetic analysis, Tc323 is highly conserved throughout evolution in all the lineages of T. cruzi so far identified, but it is absent in Leishmania spp. and Trypanosoma brucei. Most interestingly, only plasma samples from patients infected with T. cruzi and those with mixed infection with Leishmania spp. reacted against Tc323. Collectively, our findings demonstrate that Tc323 is a promising candidate for the differential serodiagnosis of chronic Chagas disease in areas where T. cruzi and Leishmania spp. infections coexist.
- 18 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1202
Open AccessCharacterization of Novel Trypanosoma cruzi-Specific Antigen with Potential Use in the Diagnosis of Chagas Disease
Chagas disease is caused by the parasite Trypanosoma cruzi. In humans, it evolves into a chronic disease, eventually resulting in cardiac, digestive, and/or neurological disorders. In the present study, we characterized a novel T. cruzi antigen named Tc323 (TcCLB.504087.20), recognized by a single-chain monoclonal antibody (scFv 6B6) isolated from the B cells of patients with cardiomyopathy related to chronic Chagas disease. Tc323, a ~323 kDa protein, is an uncharacterized protein showing putative quinoprotein alcohol dehydrogenase-like domains. A computational molecular docking study revealed that the scFv 6B6 binds to an internal domain of Tc323. Immunofluorescence microscopy and Western Blot showed that Tc323 is expressed in the main developmental forms of T. cruzi, localized intracellularly and exhibiting a membrane-associated pattern. According to phylogenetic analysis, Tc323 is highly conserved throughout evolution in all the lineages of T. cruzi so far identified, but it is absent in Leishmania spp. and Trypanosoma brucei. Most interestingly, only plasma samples from patients infected with T. cruzi and those with mixed infection with Leishmania spp. reacted against Tc323. Collectively, our findings demonstrate that Tc323 is a promising candidate for the differential serodiagnosis of chronic Chagas disease in areas where T. cruzi and Leishmania spp. infections coexist.
- Open Access
- 22 August 2023
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 41, 48-51
First case report of tinea corporis caused by Trichophyton indotineae in Latin America
- 22 August 2023
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 41, 48-51
Open AccessFirst case report of tinea corporis caused by Trichophyton indotineae in Latin America
- Open Access
- 25 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 11875
Trypanosoma cruzi Secreted Cyclophilin TcCyP19 as an Early Marker for Trypanocidal Treatment Efficiency
Cyclophilins (CyPs) are a family of enzymes involved in protein folding. Trypanosoma cruzi, the causative agent of Chagas disease, has a 19-kDa cyclophilin, TcCyP19, that was found to be secreted in parasite stages of the CL Brener clone and recognized by sera from T. cruzi-infected mice and patients. The levels of specific antibodies against TcCyP19 in T. cruzi-infected mice and subjects before and after drug treatment were measured by an in-house enzyme linked immunosorbent assay (ELISA). Mice in the acute and chronic phase of infection, with successful trypanocidal treatments, showed significantly lower anti-TcCyP19 antibody levels than untreated mice. In children and adults chronically infected with T. cruzi, a significant decrease in the anti-TcCyP19 titers was observed after 12 months of etiological treatment. This decrease was maintained in adult chronic patients followed-up 30–38 months post-treatment. These results encourage further studies on TcCyP19 as an early biomarker of trypanocidal treatment efficiency.
- 25 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 11875
Open AccessTrypanosoma cruzi Secreted Cyclophilin TcCyP19 as an Early Marker for Trypanocidal Treatment Efficiency
Cyclophilins (CyPs) are a family of enzymes involved in protein folding. Trypanosoma cruzi, the causative agent of Chagas disease, has a 19-kDa cyclophilin, TcCyP19, that was found to be secreted in parasite stages of the CL Brener clone and recognized by sera from T. cruzi-infected mice and patients. The levels of specific antibodies against TcCyP19 in T. cruzi-infected mice and subjects before and after drug treatment were measured by an in-house enzyme linked immunosorbent assay (ELISA). Mice in the acute and chronic phase of infection, with successful trypanocidal treatments, showed significantly lower anti-TcCyP19 antibody levels than untreated mice. In children and adults chronically infected with T. cruzi, a significant decrease in the anti-TcCyP19 titers was observed after 12 months of etiological treatment. This decrease was maintained in adult chronic patients followed-up 30–38 months post-treatment. These results encourage further studies on TcCyP19 as an early biomarker of trypanocidal treatment efficiency.
- Open Access
- 10 July 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (8) , ofad357
Molecular Characterization of Trypanosoma cruzi Reactivation and Follow-up in a Case Series of People With HIV
We characterize Trypanosoma cruzi infections from blood and cerebrospinal fluid samples in a case series of people with human immunodeficiency virus and Chagas disease. We identify different infecting T. cruzi populations, highlighting the usefulness of real-time polymerase chain reaction for Chagas disease reactivation diagnosis and evaluation of treatment response.
- 10 July 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (8) , ofad357
Open AccessMolecular Characterization of Trypanosoma cruzi Reactivation and Follow-up in a Case Series of People With HIV
We characterize Trypanosoma cruzi infections from blood and cerebrospinal fluid samples in a case series of people with human immunodeficiency virus and Chagas disease. We identify different infecting T. cruzi populations, highlighting the usefulness of real-time polymerase chain reaction for Chagas disease reactivation diagnosis and evaluation of treatment response.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 56, e0549-2023
Guidelines for Trypanosoma cruzi-HIV Co-infection and other Immunosuppressive Conditions: Diagnosis, Treatment, Monitoring, and Implementation from the International Network of Care and Studies - 2023
Since the Brazilian Ministry of Health’s 1992 revision to the case definition of acquired immunodeficiency syndrome (AIDS), there has been scientific evidence showing that certain endemic infectious and parasitic processes, such as Chagas disease, visceral leishmaniasis, and paracoccidioidomycosis, can induce opportunistic behaviour in individuals with advanced Human Immunodeficiency Virus (HIV). This situation requires distinct clinical protocols within the healthcare network and epidemiological surveillance measures. These actions aim to incorporate clinical events as indications of AIDS.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 56, e0549-2023
Open AccessGuidelines for Trypanosoma cruzi-HIV Co-infection and other Immunosuppressive Conditions: Diagnosis, Treatment, Monitoring, and Implementation from the International Network of Care and Studies - 2023
Since the Brazilian Ministry of Health’s 1992 revision to the case definition of acquired immunodeficiency syndrome (AIDS), there has been scientific evidence showing that certain endemic infectious and parasitic processes, such as Chagas disease, visceral leishmaniasis, and paracoccidioidomycosis, can induce opportunistic behaviour in individuals with advanced Human Immunodeficiency Virus (HIV). This situation requires distinct clinical protocols within the healthcare network and epidemiological surveillance measures. These actions aim to incorporate clinical events as indications of AIDS.
- Open Access
- 31 August 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (4) , e0135722
Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole
This study identified the risk factors for the development of adverse reactions to benznidazole and identified a set molecule to monitor the appearance of these reactions. This knowledge might improve the safety of benznidazole administration.
- 31 August 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (4) , e0135722
Open AccessMixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole
This study identified the risk factors for the development of adverse reactions to benznidazole and identified a set molecule to monitor the appearance of these reactions. This knowledge might improve the safety of benznidazole administration.